What follows covers the typical age window, how clinicians stage the transition, what can move the timing earlier, which symptoms arrive first, and what blood work can and cannot tell you during these years.
Most women begin perimenopause in their 40s. Clinical reviews of the perimenopause describe it as typically starting in the 40s, with the final menstrual period most often arriving around age 51 1. The spread around that average is wide. Some women notice the first changes in their late 30s. Others still have predictable cycles at 49 or 50 and move through the whole transition in two or three years.
Age is a useful starting assumption, not a verdict. Two women born in the same year can be at completely different points, because what matters is the state of the ovaries rather than the birthday. That is why a clinician asks about your cycle pattern over the past twelve months before anything else, and why a single blood draw rarely settles the question on its own.
It also helps to separate three words that get used interchangeably. Perimenopause is the stretch of time when cycles and hormones are changing but periods have not stopped. Menopause is a single point in time, the final menstrual period, and it can only be identified in hindsight after twelve consecutive months without bleeding. Postmenopause is everything after that point.
So the answer has two halves. The typical window for the start of perimenopause is the 40s, and the typical window for the end is the early 50s, with real variation at both edges. If cycles changed noticeably before age 40, that is a different conversation and one worth having with a clinician rather than waiting out.
The ovaries run low on the follicles that make hormones, ovulation becomes intermittent, and the feedback loop between the brain and the ovaries loses its steadiness. That loss of steadiness, more than any single low hormone level, is what produces the experience of perimenopause.
In a reproductive-age cycle, a cohort of follicles is recruited each month, one becomes dominant, estradiol rises, ovulation happens, and progesterone follows in the second half of the cycle. As the follicle pool shrinks, the ovary sends weaker signals back to the pituitary, so the pituitary pushes harder by raising FSH to recruit what is left. Higher FSH is the body working harder for the same result, not a switch being flipped.
The common assumption is that estrogen simply falls. It is messier than that. Reviews of the perimenopause describe estradiol as erratic during the transition, with episodes that can run higher than in younger cycles as well as periods when it drops 1. Cycles with no ovulation also mean less progesterone in the second half of the month, which is part of why bleeding can become heavier or less predictable.
This explains a pattern that confuses a lot of people. Symptoms often track change and withdrawal rather than a steady low level, which is why someone can feel hot flashes, disrupted sleep and mood swings in the same month that a lab result comes back looking entirely ordinary.
Staging is done by cycle pattern first, with hormone levels as supporting information. The most widely used framework is the Stages of Reproductive Aging Workshop +10 system, which anchors everything to the final menstrual period and uses bleeding pattern as the principal criterion, with endocrine measures as supportive 2.
| Stage | What the cycle looks like | What labs may show |
|---|---|---|
| Late reproductive | Cycles still regular, with subtle shortening and changes in flow | AMH low, antral follicle count low, early follicular FSH variable |
| Early menopausal transition | A persistent difference of 7 days or more between consecutive cycle lengths | FSH variable and rising on some draws |
| Late menopausal transition | An interval of 60 days or more with no period | FSH higher on many draws, estradiol variable |
| Early postmenopause | Twelve months have passed since the final period | FSH high, estradiol low |
The bleeding criteria in that table are the staging criteria set out in the Stages of Reproductive Aging Workshop +10 summary 2. Lab values shown are typical directions of travel rather than diagnostic cut-offs, and reference ranges vary by lab, age and assay.
The practical value of staging is orientation. Knowing that you are in the early transition rather than the late transition tells you something about what to expect next, about whether periods are likely to space out soon, and about how a clinician will interpret a given symptom. It also makes clear why a single number cannot do the job that a twelve-month bleeding history does.
The first reliable sign is a persistent change in cycle length, not a missed period. In the staging framework, the early menopausal transition is marked by a persistent difference of 7 days or more in the length of consecutive cycles, and the late transition is marked by an interval of 60 days or more without a period 2.
The word persistent matters. One odd month after illness, travel, heavy training or a stressful stretch does not qualify. What counts is a pattern that recurs. Many women find their cycles get shorter before they get longer, so a 28 day cycle becoming a 24 day cycle can be an earlier signal than a skipped month.
Flow changes are common alongside length changes. Bleeding can become heavier, lighter, or more variable from month to month. Heavier or more frequent bleeding is worth raising with a clinician rather than assuming it is simply part of the transition, because other causes of abnormal bleeding exist at this age and some of them are easy to identify.
Two practical points. First, ovulation still happens in many perimenopausal cycles, so pregnancy remains possible and a pregnancy test is a reasonable step when a period is missed. Second, tracking helps more than almost any test. Logging the first day of bleeding for six to twelve months gives a clinician the single most useful piece of data for placing you in the transition.
It varies widely, commonly running for several years, and it formally ends twelve months after the final menstrual period 2. Some women pass through in a couple of years. Others experience changing cycles and symptoms for much longer.
The late part of the transition, when gaps of 60 days or more appear, tends to be shorter than the early part but is often the most symptomatic stretch, because hormonal swings are at their widest.
Symptoms do not politely stop when periods do. Findings from the Study of Women's Health Across the Nation indicate that vasomotor symptoms such as hot flashes and night sweats frequently persist for years and can continue beyond the final menstrual period 3. That is worth knowing in advance, because many people plan around the idea that the last period is the finish line.
The twelve month rule also has a practical catch. Because menopause is confirmed only in retrospect, you cannot know in the moment that a given period is the last one. This is why clinicians treat the transition as a span to be managed rather than a date to be predicted, and why any decision about symptom care is reviewed over time rather than made once.
Genetics is the strongest single influence on timing, and certain medical events can move it abruptly. If your mother or sisters went through the transition early, that is useful context for your own expectations, although it is not a prediction.
Some causes are direct. Clinical practice guidance on menopause and the perimenopause covers menopause that is induced rather than spontaneous, including after surgical removal of both ovaries or after cancer therapy, where the change arrives suddenly rather than gradually 4. The same guidance addresses loss of ovarian function before age 40, which has recognized genetic, autoimmune and iatrogenic causes and is evaluated differently from a typical transition 4.
Smoking status, previous pelvic surgery, pelvic radiation, and a family history of early menopause are all things a clinician asks about when the timing looks early, because each changes how the picture is read.
A common question is whether lifestyle can delay the transition. Body composition, training load, stress and nutrition all influence how cycles behave month to month and how symptoms feel, and severe energy deficit or very high training volume can stop periods entirely at any age. That is a different mechanism from ovarian aging, and it is one of the reasons a clinician looks at the whole context rather than assuming that disrupted cycles in the 40s must be perimenopause.
No single blood test can confirm it. Perimenopause is a clinical call based on age, symptoms and cycle pattern, and the staging framework regards bleeding criteria as the principal criteria with hormone measures as supportive 2.
The reason is biological, not technical. FSH and estradiol fluctuate substantially from cycle to cycle and even week to week during the transition, which is why clinical reviews caution against relying on an isolated measurement 1. A woman with clear perimenopausal symptoms can produce a completely unremarkable FSH result one month and an elevated one the next. Neither result is wrong, and neither one is the answer.
For orientation, a typical lab reference range for FSH in premenopausal women runs around 1 to 15 mIU/mL, measured in the early follicular phase, while FitScript's optimal range is 1.5 to 10 mIU/mL. Optimal ranges are optimization targets rather than diagnostic cut-offs, and reference ranges vary by lab, by assay and by the day of the cycle the sample was drawn.
There are situations where hormone testing earns its place. When periods stop before age 40, when the picture does not fit the age, or when another cause is suspected, testing adds real information, especially when repeated rather than read once. The useful framing is this. A result tells you what the hormones were doing on the morning of the draw. Your cycle history tells you what your ovaries have been doing all year.
AMH shifts the odds at a group level, but it does not fix a date for an individual. A systematic review of anti-Mullerian hormone for the diagnosis and prediction of menopause found that AMH is associated with the timing of menopause while concluding that prediction for an individual woman remains imprecise 5.
AMH is produced by small growing follicles, so it reflects the size of the remaining pool and declines as that pool shrinks. That makes it a more stable marker across the cycle than FSH, which is why it appears in the supportive criteria for the late reproductive stage.
Where people go wrong is treating AMH as a countdown clock. A low AMH in the 40s is largely expected and does not mean the final period is imminent, and a reassuringly higher AMH does not promise years of regular cycles. It is one input among several, read alongside age, cycle pattern and symptoms.
AMH is also not a fertility score. It says something about the quantity of remaining follicles and very little about egg quality or the chance of conception in a given month. Anyone making decisions about fertility in this window should have that conversation with a clinician who can interpret the number against the full picture rather than in isolation.
During the transition, blood work earns most of its value by ruling other explanations in or out rather than by confirming perimenopause itself. Fatigue, weight change, heavy bleeding, low mood, palpitations and poor sleep all have more than one possible cause at this age, and several of them are checkable.
Thyroid markers are the classic example, because thyroid conditions can produce symptoms that overlap closely with the transition. Clinical practice guidance on the perimenopause addresses the need to consider alternative explanations for midlife symptoms rather than attributing everything to ovarian aging 4. A pregnancy test is a sensible step when a period is missed and pregnancy is possible. A complete blood count and iron markers such as ferritin matter when bleeding has become heavy, because iron depletion can build quietly over months of heavier cycles.
Midlife is also a sensible moment to look at cardiometabolic markers. Recommendations on women's midlife health emphasize assessing cardiovascular and bone health around this life stage rather than waiting until later 6. In practice that often means lipids, fasting glucose and markers of insulin resistance, plus a view of bone health where risk factors are present. A women's hormone and menopause panel typically groups the reproductive hormones with thyroid and metabolic markers for exactly this reason.
One principle holds throughout. A value outside the standard range is an observation, not a diagnosis. It may reflect the transition, it may reflect something else entirely, and what it means for you is worth discussing with a clinician who can see the whole picture.
Cycle changes usually come first, followed for many women by hot flashes, night sweats and disrupted sleep. Vasomotor symptoms can begin while periods are still fairly regular, which surprises people who expect them only after periods stop.
Research suggests that hot flashes arise from a narrowing of the body's thermoneutral zone, the small temperature band within which you neither sweat nor shiver, so that a minor rise in core temperature triggers flushing and sweating 7. The same work describes estrogen withdrawal rather than a fixed low estrogen level as the relevant trigger for these changes in thermoregulatory control 7. That is why the symptom pattern often tracks hormonal swings rather than a single measurement.
Other early changes include heavier or more erratic bleeding, breast tenderness, headaches around the cycle, and a lower tolerance for the same training load or the same glass of wine. Genitourinary symptoms such as vaginal dryness and discomfort with intercourse tend to arrive later and, unlike hot flashes, generally do not resolve on their own.
The symptom experience varies enormously between individuals. Findings from the Study of Women's Health Across the Nation describe substantial variation in symptom burden and trajectory across the transition rather than one universal pattern 3. Comparing your experience to a friend's tells you very little, which is another argument for tracking your own symptoms against your own cycle.
Some of it is hormonal and some of it is downstream of broken sleep. Studies indicate that sleep difficulties and depressive symptoms are more common during the menopause transition than in the years before it 3.
Night sweats are part of the mechanism. A few weeks of fragmented sleep is enough to blunt concentration, shorten patience and flatten mood in anyone, independent of hormones.
Cognitive complaints in this window are extremely common. Word finding, short term recall and the sense of mental speed are the usual ones. These symptoms are real and they deserve to be taken seriously rather than dismissed, and they are also worth checking against other explanations, including thyroid function, iron status, sleep apnea and untreated low mood.
The practical approach is to separate the layers. Address the thing waking you at 3am, look at the markers that have their own fix, and track whether the mental symptoms move with your cycle or sit flat across the month. That distinction is genuinely informative and it is something you can gather before any appointment.
The years immediately around the final menstrual period are when several long-term health trajectories change direction. Findings from the Study of Women's Health Across the Nation describe accelerating bone loss and adverse shifts in cardiometabolic and body composition measures across the menopause transition 3.
That is why midlife guidance treats this window as a risk assessment opportunity. Recommendations on women's midlife health and menopause emphasize attention to cardiovascular risk, bone health and metabolic health at this life stage 6. Checking lipids, glucose regulation and bone risk factors in the 40s is more useful than discovering a trend in the 60s.
Body composition shifts are the change most women notice first. Lean mass becomes harder to hold and fat distribution tends to move toward the midsection, often with no change in habits. This is not a willpower problem. It does mean that the training and nutrition approach that worked at 32 may need adjusting at 47, usually in the direction of more resistance training, more protein and more attention to sleep and recovery.
None of this is inevitable in its severity. The point of measuring during the transition rather than after it is that trends are easier to influence while they are forming, and that you get a personal baseline rather than a population average to compare against later.
Loss of ovarian function before age 40 is classified as premature ovarian insufficiency, and menopause between 40 and 45 is generally described as early menopause. Clinical practice guidance on menopause and the perimenopause sets out the evaluation of ovarian insufficiency occurring before age 40 as a distinct clinical situation rather than a variation of normal timing 4.
This matters for two reasons. The first is diagnostic. Periods that stop or become very irregular before 40 need a proper assessment, because the cause may be identifiable and may have implications beyond the cycle itself. The second is long term. A longer span of life with low estrogen levels has implications for bone and cardiovascular health, which is why the guidance addresses management in this group specifically 4.
If your periods have stopped or changed dramatically before 40, that is worth discussing with a clinician promptly rather than monitoring for another year. Testing in that situation is far more informative than it is in a 47 year old with gradually shortening cycles, and it usually involves repeated measurements rather than a single draw.
The reverse case, cycles that remain regular into the early 50s, is also a normal variant. Later timing is not a problem to be corrected, although any bleeding that starts again after twelve months without a period should be assessed promptly.
Options during the transition range from symptom targeted lifestyle changes through to prescribed hormone care, and a licensed provider decides what is appropriate after evaluating your history, symptoms and risk profile. Recommendations on midlife health describe decisions about menopause care as individualized to the woman's symptoms, health history and preferences 6.
On the non-prescription side, the levers that tend to matter are consistent sleep timing, resistance training to protect lean mass and bone, adequate protein, managing known hot flash triggers such as alcohol and overheated rooms, and addressing iron status when bleeding has been heavy. None of these are glamorous and all of them are within your control.
On the prescription side, hormone care for women is one of the options a provider can discuss, and whether it is suitable depends on an individual evaluation. This page does not give doses, schedules or administration guidance, because those decisions belong to the provider who has reviewed your full history. FitScript works with licensed providers across all 50 states; specific treatment availability can vary by state and is confirmed during your provider evaluation.
What you can usefully bring to that evaluation is data. Twelve months of cycle dates, a short symptom log with severity and timing, and recent blood work covering thyroid, iron and metabolic markers will shape the conversation far more than a single hormone value will.
Some patterns should not wait for the next routine appointment. Any bleeding after twelve consecutive months with no period, bleeding that soaks through protection hourly or lasts much longer than usual, bleeding between periods or after intercourse, and periods stopping before age 40 are all worth discussing with a clinician promptly.
The same applies to symptoms that are disrupting your work, your sleep or your relationships. A symptom being common does not mean it has to be endured, and the decision about what, if anything, to do about it belongs to a clinician who can evaluate you properly.
It is also worth a conversation when results do not fit the story. A lab value outside the standard range in your 40s may reflect the transition, or it may reflect something else that deserves its own attention, and neither possibility should be ignored. Bring the result to a clinician rather than filing it away.
This article is educational and is not medical advice. Discuss your results, your symptoms and any treatment decision with a clinician or licensed provider who can evaluate your individual situation.
For the cognitive side of this transition, the guide on brain fog perimenopause goes deeper into why word finding and concentration change during these years and which markers are worth checking alongside the hormonal picture. It pairs well with this page if memory and mental clarity are the symptoms bothering you most.
Most women notice the first changes in their 40s, and the final period arrives for most around the early 50s. Some women see cycle changes in their late 30s and others still have regular cycles at 50. Age gives you a rough expectation, not an answer, because the cycle pattern is what places you in the transition.
Yes, some women notice cycle changes in their late 30s and that can be within the normal range. Periods that stop entirely or become very irregular before age 40 are a different situation and should be assessed by a clinician rather than monitored for another year. Testing is far more useful in that scenario than it is at 47.
You cannot know from symptoms alone, because fatigue, weight change, poor sleep and low mood all have more than one possible cause at this age. A clinician looks at your age, your cycle pattern over the past year and your symptoms, then uses blood work mainly to check other explanations such as thyroid or iron status. Bring a cycle log to the appointment, since it is the single most useful piece of information.
No. FSH moves substantially from one cycle to the next during the transition, so a result in the typical range on one morning does not rule anything out, and a high result on another morning does not confirm anything either. A single value describes that moment only. Repeated measurements interpreted alongside your cycle history are far more informative.
It varies a great deal, commonly running for several years, and it formally ends twelve months after your final period. The later stage, when gaps of two months or more appear between periods, is often shorter but more symptomatic. Because the final period is only identified in hindsight, no one can tell you the end date in advance.
Yes. Ovulation still happens in many perimenopausal cycles, so pregnancy remains possible until twelve consecutive months have passed without a period. A pregnancy test is a reasonable step when a period is missed. Contraception decisions during this window are worth discussing with a clinician.
Thyroid markers, a complete blood count and iron markers such as ferritin if bleeding has been heavy, and metabolic markers such as lipids and fasting glucose are the ones that most often change what happens next. Reproductive hormones can be included, but they are read as supporting information rather than as confirmation. A clinician decides which tests make sense for your situation.
Promptly if you have bleeding after twelve months with no period, very heavy or prolonged bleeding, bleeding between periods, or periods that stop before age 40. Also worth an appointment if symptoms are disrupting your sleep, work or relationships. Any decision to start, stop or change a treatment belongs to a licensed provider after an evaluation.